REFERENCES

• RhodesSMCoghillDRMatthewsKMethylphenidate restores visual memory but not working memory function in attention deficit hyperkinetic disorderPsychopharmacol2004175319330
   PubMed Web of Science ®Google Scholar
• PirontiVALaiM-CMullerUet alNeuroanatomical abnormalities and cognitive impairments are shared by adults with attention deficit/hyperactivity disorder and their unaffected first-degree relativesBiol Psychiatry20147663964724199662
   PubMed Web of Science ®Google Scholar
• FaraoneSVUsing meta-analysis to compare the efficacy of medications for attention deficit/hyperactivity disorder in youthsPT.200934678683
   PubMedGoogle Scholar
• FaraoneSVGlattSJA comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizesJ Clin Psychiatry201019754763
   Google Scholar
• FaraoneSVBuitelaarJComparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysisEur Child Adolesc Psychiatry20101935336419763664
   PubMed Web of Science ®Google Scholar
• CorteseSAdamaNDel GiovaneCet alComparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisLancet 
Psychiatry2018572773830097390
   PubMed Web of Science ®Google Scholar
• BiedermanJMonuteauxMCSpencerTWilensTEFaraoneSVDo stimulants have a protective effect on the development of psychiatric disorders in youth with ADHD? A ten-year follow-up studyPediatrics2009124717819564285
   PubMed Web of Science ®Google Scholar
• EiiaJWelshPAGulottaCSRapaportJLClassroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boysJ Child Psychol Psychiatry1993347858048340445
   PubMed Web of Science ®Google Scholar
• LoeIMFeldmanHMAcademic and Educational Outcomes of Children With ADHDJ Ped Psychol200732643654
   PubMed Web of Science ®Google Scholar
• ArnoldLEHodgkinsPKahleJMadhooMKewleyGLong-term outcomes of ADHD: academic achievement and performanceJ Attention Dis201519113
   Google Scholar
• NakaoTRaduaJRubiaKMataix-ColsDGray matter volume abnormalities in ADHD: Voxel based meta-analysis exploring the effects age and stimulant medicationAm. J Psychiatry20111681154116321865529
   PubMed Web of Science ®Google Scholar
• ChamberlainSRRobbinsTWWinder-RhodesSet alTranslational approaches to frontostriatal dysfunction in attention deficit/hyperactivity disorder using a computerized neuropsychological batteryBiol Psychiatry2011691192120321047621
   PubMed Web of Science ®Google Scholar
• DeVitoEBlackwellADKentLet alThe effects of methylphenidate on decision making in attention-deficit/hyperactivity disorderBiol Psychiatry20086463663918504036
   PubMed Web of Science ®Google Scholar
• CoolsRBarkerRSahakianBJRobbinsTWEnhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demandsCereb Cortex2001111136114311709484
   PubMed Web of Science ®Google Scholar
• CoolsRBarkerRASahakianBJRobbinsTWL-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s diseaseNeuropsychologia2003411431144112849761
   PubMed Web of Science ®Google Scholar
• SpragueRLSleatorEKMethylphenidate in hyperkinetic children: differences in dose effects on learning and social behaviorScience197719812741276337493
   PubMed Web of Science ®Google Scholar
• del CampoNChamberlainSRSahakianBJRobbinsTWThe roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit hyperactivity disorderBiol Psychiatry201169e14515721550021
   PubMed Web of Science ®Google Scholar
• RobbinsTW Arnsten AFTThe neuropsychopharmacology of fronto-executive function: monoaminergic modulationAnn Rev Neurosci20093226728719555290
   PubMed Web of Science ®Google Scholar
• BariAMarACTheobaldDEHet alPrefrontal and monoaminergic contributions to top-
signal performance in ratsJ Neurosci2011319254926321697375
   PubMed Web of Science ®Google Scholar
• ChamberlainSRDel CampoNDowsonJet alAtomoxetine improved response inhibition in adults with attention-deficit/hyperactivity disorderBiol Psychiatry20076297798417644072
   PubMed Web of Science ®Google Scholar
• Aston-JonesGChiangCAlexinskyTDischarge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilanceProg Brain Res1991885015201813931
   PubMed Web of Science ®Google Scholar
• LapizMDMorilakANoradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capabilityNeurosci200613710391049
   PubMed Web of Science ®Google Scholar
• Goldman-RakicPSCellular basis of working memoryNeuron1995144774857695894
   PubMed Web of Science ®Google Scholar
• GranonSPassettiFThomasKLDalleyJWEverittBJRobbinsTWEnhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortexJ Neurosci2000201208121510648725
   PubMed Web of Science ®Google Scholar
• del CampoNFryerTDHongYTet alA positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatmentBrain20131363252327024163364
   PubMed Web of Science ®Google Scholar
• TurnerDCRobbinsTWClarkLAronARDowsonJSahakianBJCognitive enhancing effects of modafinil in healthy volunteersPsychopharmacol2003165260269
   PubMed Web of Science ®Google Scholar
• TurnerDCClarkLDowsonJRobbins TWSahakianBJModafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorderBiol Psychiatry2004551031104015121488
   PubMed Web of Science ®Google Scholar
• MinzenbergMRCameronCSModafinil: A review of neurochemical actions and effects on cognitionNeuropsychopharmacol20083314771502
   PubMed Web of Science ®Google Scholar
• ScorielsLJonesPBSahakianBJModafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brainNeuropharmacol201364168184
   PubMed Web of Science ®Google Scholar
• CastnerSWilliamsGVGoldman-RakicPSReversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulationScience20002872020202210720329
   PubMed Web of Science ®Google Scholar
• HusaAMoilanenJMurrayGKet alLifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohortPsychiatry Res201724713013827888683
   PubMed Web of Science ®Google Scholar
• VeselinovicTScharpenbergMHeinzeMet alDisparate effects of first and second generation anti-psychotics on cognition in schizophrenia – Findings from the randomized NeSSy trialEur J Neuropsychopharmacol201929720739
   PubMed Web of Science ®Google Scholar
• KeefeRSBilderRMDavisSMet alNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialArch Gen Psychiatry20076463364717548746
   PubMed Web of Science ®Google Scholar
• LeesonVCRobbinsTWMathesonEet alDiscrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndromeBiol Psychiatry20096658659319576575
   PubMed Web of Science ®Google Scholar
• SinkeviciuteIBegemannMPrikkenMet alEfficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysisNPI Schizophrenia2018422https://doi.org/10.1038/s41537-018-0064-6
   PubMed Web of Science ®Google Scholar
• MoghaddamBJavittDFrom revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatmentNeuropsychopharmacol201237415
   PubMed Web of Science ®Google Scholar
• KinonBJMillenBAZhangLMcKinzieDLExploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophreniaBiol Psychiatry20157875476225890643
   PubMed Web of Science ®Google Scholar
• SuppiramaniamVBahrBASinnarajahSet alMember of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptorsSynapse20014015415811252027
   PubMed Web of Science ®Google Scholar
• SeninUAbateGFieschiCet alAniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical studyEur Neuropsychopharmacol199115115171822317
   PubMedGoogle Scholar
• KoliakiCCMessiniCTsolakiMClinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open studyCNS Neurosci Ther20121830231222070796
   PubMed Web of Science ®Google Scholar
• WesnesKAnandRSimpsonPChristmasLThe use of a scopolamine mo2del to study the potential nootropic effects of aniracetam and piracetam in healthy volunteersJ Psychopharmacol1990421923222281851
   PubMedGoogle Scholar
• LawrenceADSahakianBJThe cognitive psychopharmacology of Alzheimer’s disease: focus on cholinergic systemsNeurochem Res1998237877949566619
   PubMed Web of Science ®Google Scholar
• EmreMAarslandDAlbaneseAet alRivastigmine for dementia associated with Parkinson’s diseaseN Engl J Med20043512509251815590953
   PubMed Web of Science ®Google Scholar
• HaigGMBainEERobiesonWZet alA randomized trial to assess the efficacy and safety of ABT-126, a selective a7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophreniaAm J Psychiatry201617382783526940805
   PubMed Web of Science ®Google Scholar
• HaigGWangDOthmanA.A.ZhaoJThe alpha7 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in nonsmokers: Results from a randomized controlled phase 2b studyNeuropsychopharmacol20164128932902
   PubMed Web of Science ®Google Scholar
• DanielDGWeinbergerDRJonesDWThe effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophreniaJ Neurosci19911719071917
   Google Scholar
• BarchDMCarterCSAmphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteersSchiz Res2005774358
   PubMed Web of Science ®Google Scholar
• TurnerDCClarkLPomarol-ClotetEet alModafinil improves cognition and attentional set shifting in patients with chronic schizophreniaNeuropsychopharmacol20042913631373
   PubMed Web of Science ®Google Scholar
• LeesJMichalopoulouPGLewisSWModafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trialPsychol Med2017472358236828464963
   PubMed Web of Science ®Google Scholar
• ElliottRSahakianBJMcKayAPet alNeuropsychological impairments in unipolar depression: the influence of perceived failure on subsequent performancePsychol Med1996269759898878330
   PubMed Web of Science ®Google Scholar
• PradoCEWattSCroweSFA meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samplesNeuropsychol Rev201828327229446012
   PubMed Web of Science ®Google Scholar
• McIntyreRSLophavenSOlsenCKA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adultsInt J Neuropsychopharmacol2014171557156724787143
   PubMed Web of Science ®Google Scholar
• SanchezCAsinKEArtigasFVortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical dataPharmacol Ther2015145435725016186
   PubMed Web of Science ®Google Scholar
• GossAJKaserMCostafredaSGSahakianBJFuCHYModafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trialsJ Clin Psychiatry2013741101110724330897
   PubMed Web of Science ®Google Scholar
• KaserMDeakinJBMichaelAet alModafinil improves episodic memory and working memory cognition in patients with remitted depression: A double-blind, randomized, placebo-controlled studyBiol Psychiatr Cogn Neurosci Neuroimaging20172115122
   PubMedGoogle Scholar
• GuestellaAJEinfeldSLGrayKMet alIntranasal oxytocin improves emotion recognition for youth with autism spectrum disordersBiol Psychiatry20106769269419897177
   PubMed Web of Science ®Google Scholar